

# An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)

Update on Immunization in Pregnancy with  
Tetanus Toxoid, Reduced Diphtheria Toxoid and  
Reduced Acellular Pertussis (Tdap) Vaccine

PROTECTING AND EMPOWERING CANADIANS TO IMPROVE THEIR HEALTH



Public Health  
Agency of Canada

Agence de la santé  
publique du Canada

Canada

**TO PROMOTE AND PROTECT THE HEALTH OF CANADIANS THROUGH LEADERSHIP, PARTNERSHIP,  
INNOVATION AND ACTION IN PUBLIC HEALTH.**

—Public Health Agency of Canada

Également disponible en français sous le titre :

Mise à jour sur l'immunisation durant la grossesse avec le vaccin combiné anti-Tétanos, et à dose réduite contre la diphtérie et la coqueluche acellulaire (dcaT)

This publication can be made available in alternative formats upon request.

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2018

Publication date: **February 2018**

This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged. However, multiple copy reproduction of this publication in whole or in part for purposes of resale or redistribution requires the prior written permission from the Minister of Public Works and Government Services Canada, Ottawa, Ontario K1A 0S5 or [copyright.droitdauteur@pwgsc.gc.ca](mailto:copyright.droitdauteur@pwgsc.gc.ca).

Cat.: **HP40-207/2018D-PDF**

ISBN: **978-0-660-25133-2**

Pub.: **170472**

## PREAMBLE

The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada (PHAC) with ongoing and timely medical, scientific, and public health advice relating to immunization. PHAC acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and is disseminating this document for information purposes. People administering the vaccine should also be aware of the contents of the relevant product monograph(s). Recommendations for use and other information set out herein may differ from that set out in the product monograph(s) of the Canadian manufacturer(s) of the vaccine(s). Manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. NACI members and liaison members conduct themselves within the context of the PHAC Policy on Conflict of Interest, including yearly declaration of potential conflict of interest.

## TABLE OF CONTENTS

SUMMARY OF INFORMATION CONTAINED IN THIS NACI STATEMENT.....	4
I. INTRODUCTION .....	5
II. METHODS.....	5
III. EPIDEMIOLOGY .....	7
IV. VACCINE.....	10
V. RECOMMENDATIONS.....	15
VI. RESEARCH AND EVALUATION PRIORITIES.....	19
VII. SURVEILLANCE AND MONITORING ISSUES .....	20
TABLES.....	21
LIST OF ABBREVIATIONS .....	23
ACKNOWLEDGMENTS .....	24

## SUMMARY OF INFORMATION CONTAINED IN THIS NACI STATEMENT

The following highlights key information for immunization providers. Please refer to the remainder of the Statement for details.

### 1. What

Pertussis caused by *Bordetella pertussis* is an endemic respiratory disease pathogen from which unimmunized infants are at greatest risk of hospitalization and death.

### 2. Who

This statement addresses maternal<sup>1</sup> Tdap immunization in pregnancy in Canada with the aim of protecting newborn infants in Canada from severe outcomes of pertussis infection.

### 3. How

Immunization with Tdap vaccine should ideally be provided in every pregnancy between 27 and 32 weeks of gestation. However, Tdap immunization may be provided from 13 weeks up to the time of delivery in view of programmatic and unique patient considerations.

### 4. Why

Due to high susceptibility to infection, infants who have not initiated vaccination or completed the primary series of pertussis immunization are at highest risk for pertussis complications, including hospitalization and death. Immunization in pregnancy is safe and provides protection to infants until they are able to receive the pertussis vaccine at two months of age.

Due to the varying cycle activity of pertussis in Canada, routine immunization with Tdap vaccine in pregnancy is preferred over its use as an outbreak control measure only. Use of Tdap vaccine during outbreak situations is considered to be logistically challenging and less effective for preventing pertussis in infants compared to routine maternal immunization in pregnancy.

---

<sup>1</sup> NACI recognizes that not all people giving birth will identify as women or mothers. For the purposes of this statement, the terms “pregnant woman”, “mothers” and “maternal” are used, but should be considered to also apply to those individuals who do not specifically identify as female gender but are the parent gestating the fetus.

## I. INTRODUCTION

In 2013, following an approximately three-fold increase in the number of nationally reported pertussis cases, NACI adopted several recommendations pertaining to the immunization of pregnant women with a tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine. At the time, based on the reviewed evidence, NACI concluded that vaccination with Tdap vaccine in pregnancy was safe and immunogenic, and recommended that:

- depending on regional epidemiology, immunization with Tdap may be offered during pertussis outbreaks (as defined by a jurisdiction) to pregnant women who are 26 weeks of gestation or greater irrespective of their immunization history, and
- pregnant women who have not been immunized with Tdap in adulthood should be offered a pertussis vaccine.

However, in view of the low number of severe outcomes in newborns being observed in Canada, as well as the uncertainty about the potentially adverse effects of maternally derived antibodies on lowering the infant's response to immunization with diphtheria and tetanus toxoids, acellular pertussis (DTaP) vaccine, routine immunization with Tdap vaccine in pregnancy was not recommended at that time. With the availability of new effectiveness data reported following the implementation of routine maternal immunization programs internationally, the NACI Diphtheria/Tetanus/Pertussis/Polio/Haemophilus Influenza B Working Group (PWG) was again tasked with reviewing the evidence pertaining to the use of Tdap vaccine in pregnancy. In accordance with the direction that was provided by the Canadian Immunization Committee, the objective of this NACI Statement is to provide guidance on maternal immunization in pregnancy as a strategy to reduce disease incidence and severe outcomes (defined as hospitalization or death) from pertussis infection in infants less than 12 months of age.

The specific topics that were reviewed by the PWG included:

- the burden of pertussis in infants less than 12 months of age
- the safety of maternal immunization with Tdap vaccine in pregnancy
- the efficacy and effectiveness of maternal immunization with Tdap in pregnancy in preventing severe outcomes of pertussis infection in infants less than 12 months of age
- the effects of maternal Tdap immunization in pregnancy on an infant's immunological response to the primary vaccine schedule
- the impact of maternal Tdap immunization in pregnancy on long term protection against tetanus, diphtheria and pertussis in children.

## II. METHODS

The PWG reviewed evidence on the burden of disease in Canada; vaccine safety and immunogenicity; and vaccine effectiveness in jurisdictions that have implemented maternal immunization programs. The following research questions were developed by the PWG:

- Is there a significant difference in local or systemic adverse events for the mother following immunization with Tdap vaccine in pregnancy (all stages) compared to adult immunization outside pregnancy?

- Is there a significant difference in adverse fetal and neonatal health outcomes for the baby following immunization of their mother with Tdap vaccine in pregnancy?
- Is maternal immunization in pregnancy with Tdap significantly more efficacious or effective in preventing severe disease in infants under 12 months of age compared to no maternal immunization in pregnancy?
- Is the immunogenicity of DTaP vaccination in children born to mothers immunized with Tdap vaccine in pregnancy significantly different compared to infants born to mothers who were not immunized with Tdap vaccine in pregnancy?
- Does maternal immunization with Tdap in pregnancy significantly impact efficacy or effectiveness of DTaP vaccines in preventing related disease in children less than 4 to 6 years of age?

In addition to the review of unpublished data, including current international practices, a literature search and review of articles published until November 28, 2016 was conducted and updated to July 25, 2017. A total of 59 articles were identified, retrieved and included in the literature review to inform this statement. NACI and PWG members also reviewed the immunogenicity and safety data from one unpublished Canadian clinical trial (NCT00553228), which were found to be consistent with the results from other published RCTs. A detailed analysis of the relevant studies is presented in the NACI *Literature Review on Immunization in Pregnancy with Tetanus Toxoid, Reduced Diphtheria Toxoid and Reduced Acellular Pertussis (Tdap) Vaccine: Safety, Immunogenicity and Effectiveness*.

Epidemiological analysis was conducted using national surveillance data including the Canadian Notifiable Disease Surveillance System (CNDSS), the Immunization Monitoring Program Active (IMPACT) and the Canadian Institute for Health Information Discharge Abstract Database (DAD). These data are subject to limitations such as changes in reporting practices over time, number of participating institutions as well as changes in methods for laboratory detection of pertussis cases.<sup>(1-3)</sup> In general, due to the limitations of existing surveillance systems, surveillance data tend to underestimate the true number of pertussis cases.

The knowledge synthesis was performed by two technical advisors at PHAC, and supervised by the PWG. Following the critical appraisal of individual studies, summary tables with ratings of the quality of the evidence using NACI's methodological hierarchy were prepared, and proposed recommendations for vaccine use were developed.


These data tables are available in NACI's *Literature Review on Immunization in Pregnancy with Tetanus Toxoid, Reduced Diphtheria Toxoid and Reduced Acellular Pertussis (Tdap) Vaccine: Safety, Immunogenicity and Effectiveness*.

The PWG Chair presented the evidence and proposed recommendations to NACI at its meeting on June 7, 2017. Following the comprehensive evidence review and consultations, NACI voted on specific recommendations on September 27, 2017. The description of relevant considerations, rationale for specific decisions, and knowledge gaps are described in the text below.

### III. EPIDEMIOLOGY

In Canada, pertussis is an endemic and cyclical disease. Pertussis peaks occur at two- to five-year intervals, with cycle activity varying by region.<sup>(4, 5)</sup> Since the routine use of acellular pertussis vaccine in 1997/1998, there had been an overall decline in the incidence rate of pertussis until 2011.<sup>(4)</sup> Between 2012 and 2015, increased annual incidence rates were observed, ranging from 3.6 to 13.4 cases per 100,000 population.<sup>(6)</sup> The incidence peaks in 2012 and 2015 were associated with numerous outbreaks that occurred across Canada.<sup>(4, 7-10)</sup>

**Figure 1.** Annual number of reported pertussis cases in infants less than one year old in Canada by age in months, 2006-2015



\*Data were obtained from the Canadian National Notifiable Disease Surveillance System (CNDSS).


†Case data from were obtained from CNDSS. Case-level data were available for BC, AB, SK, ON, QC, PE (2010-2015), YK, and NU. Data were not available for MB, NL, NB, NS, PE, and NT (2006-2009),

Pertussis incidence varies by age group, with the greatest risk of infection and associated complications in unvaccinated or under vaccinated infants.<sup>(4-6, 10-12)</sup> Between 2006 to 2015, the average age-specific incidence rates reported through CNDSS were highest among infants less than one year of age at 71.2 cases per 100,000 population, followed by children one to nine years of age (43.0 cases per 100,000), and children ten to 19 years of age (26.1 cases per 100,000). As shown in **Figure 1**, the majority of reported cases of pertussis between 2006 and 2015 were reported in infants less than two months of age (range 60% to 74%) followed by infants three to four months of age (range 16% to 24%). A sharp increase in the number of cases was reported in 2012 in infants less than two months of age.



Pertussis-related hospitalization data reported through DAD based on primary diagnosis demonstrate that hospitalizations and admission to special care units (SCU) are disproportionately greatest in infants under one year of age.<sup>(4, 5, 12)</sup> From 2006 to 2015, the hospitalization rates associated with pertussis were 33.6 per 100,000 population in infants under one year of age and less than one per 100,000 population in other age groups. As shown in **Figure 2**, the majority of the hospitalized infants were less than two months of age (range 63% to 74%), followed by three to four months of age (range 16% to 29%). Overall, the majority of SCU admissions reported in DAD were in infants under the age of one year (320/384). Between 2006 and 2016, infants less than two months of age accounted for the largest proportion of SCU admissions (40.5%), followed by infants three to four months of age (21.4%). Similar to the pertussis incidence trend, a sharp increase in the number of hospitalization for infants under two months of age was reported in 2012.

**Figure 2.** Annual number of pertussis hospitalizations in infants less than one year old in Canada, by age in months\*‡, 2006 to 2016.<sup>(5, 6, 12)</sup>



\*Annual counts of hospitalizations less than five per age category were suppressed from the figure due to privacy issues.

‡Hospitalization data were acquired from the Canadian Institute for Health Information's Discharge Abstract Database. Hospitalization data from Quebec for 2011 to 2015 were not available for this analysis.

Lack of maternal immunity is assumed to increase infant's susceptibility to infection both by increasing the risk of disease in mothers (and subsequent transmission to the infant) and by not providing sufficient passive protection through antibody transfer (via the placenta or via breast milk). A recent cohort serosurvey has shown that the majority of pregnant women in Canada had undetectable anti-pertussis toxin levels.<sup>(13, 14)</sup> While no serologic correlate of clinical protection against pertussis currently exists, this likely indicates that i) a high proportion of pregnant women in Canada are susceptible to pertussis and ii) mothers would be unable to passively transfer pertussis-associated antibodies to newborn infants, rendering them susceptible until they start to

become protected through vaccination at two months of age.<sup>(13-19)</sup> Parents (primarily mothers) and siblings are considered to be the most important source of pertussis transmission to young infants<sup>(20-33)</sup>.

According to the national survey on adult immunization<sup>(34)</sup> (all adults 18 years of age and older), only 9.3% (95% CI, 8.1-10.5) reported having received at least one dose of acellular pertussis-containing vaccine since their 18th birthday. Considering the lack of Tdap coverage data in pregnancy due to the absence of routine maternal immunization programs in Canada, the PWG reviewed information on influenza immunization in pregnancy. A cohort study<sup>(35)</sup> that assessed influenza vaccination in pregnancy from 1990 to 2002 in NS estimated that 2.6% of all pregnant women and 6.7% of pregnant women with comorbidities received immunization. A retrospective population-based cohort study in ON from 2009 to 2010 estimated that 42.6% of women had received influenza immunization during pregnancy during the H1N1 pandemic season. In Canada, the mean age of first time mothers is 30 years, with approximately 380,000 live births annually reported since 2010.<sup>(36, 37)</sup> A recently conducted internal survey of provincial and territorial (P/T) immunization practices (unpublished) indicates that the implementation of maternal Tdap immunization programs according to 2014 NACI recommendations has been only sporadically carried out, depending on the intensity and stage of the outbreak. Logistical challenges of providing vaccination in a timely manner were cited as being a major obstacle for successful program implementation.

Additional details on the overall epidemiology of pertussis and Tdap immunization coverage in Canada are available on the [Government of Canada Immunization and vaccines](https://www.canada.ca/en/public-health/topics/immunization-vaccines.html) webpage. (<https://www.canada.ca/en/public-health/topics/immunization-vaccines.html>)

An environmental scan of international practices identified several jurisdictions where maternal Tdap immunization programs in pregnancy are currently in place. In the majority of jurisdictions these programs were implemented as part of an outbreak management strategy with a goal of reducing an increase in disease incidence rates and deaths in the less than one-year age group. Since then, in many of these countries including the US, UK, Ireland, Spain, Belgium, Switzerland, Greece, Argentina, Brazil, Colombia, Mexico and Israel, ongoing maternal Tdap immunization in pregnancy has been incorporated into routine adult immunization programs. Although the environmental scan did not identify any program evaluation reports, a detailed update on the UK maternal immunization program that was provided by Public Health England suggested a 90% effectiveness of the national program in preventing laboratory confirmed disease (95% in preventing death) in infants less than 2 months of age.<sup>(38-41)</sup>

## IV. VACCINE

### IV.1 Adult pertussis vaccine preparations authorized for use in Canada

**Table 1. Contents of adult pertussis vaccine preparations authorized for use in Canada\***

<b><u>Vaccine Ingredients</u></b>	<b><u>Adacel<sup>®</sup>, Sanofi<sup>(42)</sup></u></b>	<b><u>Boostrix<sup>®</sup>, GSK<sup>(43)</sup></u></b>
<b>Pertussis Toxin (PT, µg)</b>	2.5	8
<b>Pertussis filamentous hemagglutinin (FHA, µg)</b>	5	8
<b>Pertussis pertactin (PRN, µg)</b>	3	2.5
<b>Pertussis fimbriae (FIM 2/3, µg)</b>	5	-
<b>Diphtheria Antigen (Lf µg)</b>	2	2.5
<b>Tetanus Antigen (Lf, µg)</b>	5	5
<b>Aluminum Adjuvant (mg)</b>	1.5	0.5
<b>Other ingredients</b>	2-phenoxyethanol, water	sodium chloride, water
<b>Trace Amounts</b>	formaldehyde, glutaraldehyde	

\*Inactivated poliomyelitis vaccine (IPV) containing vaccine preparation also available (eg Adacel-Polio, Boostrix-Polio).

Based on the available trial data at the time of authorisation, none of the adult vaccine formulations have been explicitly indicated for use in pregnancy. However, according to the current product monographs, none of the adult formulations authorized for use in Canada are contraindicated for use in pregnancy.

### IV.2 Immunogenicity

During pregnancy, maternal IgG antibodies are transported across the placenta into fetal circulation, with active antibody transport increasing via the neonatal Fc receptor over the third trimester. Antibody levels to different pertussis antigens following maternal immunization have been reported for pregnant women and their infants prior to and following the receipt of infant DTaP-containing vaccines. When interpreting the results of these studies, it should be noted that a defined correlate of protection against pertussis infection remains to be determined.

#### IV.2.1 Immunogenicity for the mother during pregnancy

The literature review conducted by NACI identified fourteen relevant immunogenicity studies, four of which were RCTs. In all RCTs immune response was measured following the administration of Tdap in the third trimester of pregnancy. Compared to placebo (0.9% saline or TT), in all studies immunization increased maternal anti-PT levels at least 4-fold, while other vaccine-contained antigens increased more than 10-fold<sup>(44-46)</sup>. In RCTs that compared immune responses between women receiving Tdap during and outside of pregnancy, there were no significant differences in antibody levels. In these studies, although suppressed cellular immunity in pregnant women was noted, there were no observed differences in cellular response one year after immunization.

Other clinical and observational studies that assessed antibody responses to Tdap immunization in pregnancy reported results that were consistent with those reported in RCTs.<sup>(44-46)</sup> In the majority of reviewed studies, post immunization increases in antibody levels resulted in more than 90% of women achieving anti-PT levels  $\geq 10$  IU/ml one month following immunization.<sup>(47-49)</sup> In reviewed studies that assessed antibody persistence after immunization in pregnancy, significant decreases were observed for all pertussis antibody levels, with anti-PT concentrations declining by half, one year after immunization.<sup>(50, 51)</sup> Studies that measured antibody concentrations in colostrum and breast milk following maternal immunization in pregnancy found only modest increases in IgA and IgG anti-PT and anti-FHA levels compared to women not immunized in pregnancy.<sup>(52, 53)</sup> However, antibody levels in these studies remained detectable until at least 8 weeks after delivery, suggesting that breastfed infants could additionally benefit from the protection afforded by antibodies in breast milk.

#### IV.2.2 Maternally derived antibody levels in infants prior to the infant receipt of DTaP

Twenty one relevant studies were identified in the literature search, of which four were RCTs that reported results on maternal antibody levels in term infants. All studies provided evidence of efficient transplacental transfer of all vaccine-contained antibodies to the fetus prior to delivery.

While rapid waning of maternal antibodies within two months of birth was evident in all trials, infants born to mothers that received Tdap maintained significantly higher antibody levels compared to those observed in the control groups.<sup>(44-46, 54)</sup> These findings were also confirmed in all the reviewed observational studies.<sup>(41, 55-59)</sup> Additionally, smaller serological studies published to date suggest that maternal immunization in pregnancy does not seem to affect the selective transfer of high avidity and function-specific antibodies that can effectively stimulate infant innate immune responses (i.e. phagocytic activity of NK cells).<sup>(60-62)</sup> One study also found increased efficiency of placental antibody transfer in mothers who were immunized with Tdap compared to those who did not receive the vaccine in pregnancy.<sup>(63)</sup> With the exception of one small observational study, maternal immunization with Tdap in pregnancy was found to be more immunogenic when provided earlier in pregnancy, but after 13 weeks of gestation.<sup>(64)</sup> Compared to 31 to 36 weeks of gestation, immunization at 27 to 30 weeks of gestation was found to result in higher cord to maternal antibody ratios and anti-PT relative avidity index, with umbilical cord anti-PT avidity maturation linearly increasing with time to delivery.<sup>(65)</sup> Higher cord antibody levels (anti-PRN and anti-PT) were also reported when mothers received Tdap between 28 and 32 weeks of gestation compared to 33 to 36 weeks of gestation, and at 13 to 25 weeks of gestation when compared to immunization between 26 and 36 weeks of gestation.<sup>(66, 67)</sup> Two studies that measured anti-PT concentrations at birth following maternal immunization at less than 26 weeks of gestation, found antibody levels above 10 EU/ml to be present in over 90% of infants.<sup>(49, 67)</sup>

In studies that measured pertussis antibody levels in preterm infants, immunization during the second trimester resulted in higher concentrations as well as higher proportion of infants achieving anti-PT levels above 5 EU/ml compared to those whose mothers were immunized in the third trimester.<sup>(68, 69)</sup> In one study that assessed the effects of pregnancy body weight on neonatal antibody levels, no statistically significant differences in antibody concentrations were found between infants born to mothers with normal, overweight or obese body mass index (BMI) measurements.<sup>(70)</sup>

### IV.2.3 Immunogenicity of DTaP in infants born to women immunized with Tdap in pregnancy

Five RCTs measured immunological responses in infants following DTaP administration. In all trials, antibody levels against all pertussis antigens were lower in infants whose mothers received Tdap in the third trimester of pregnancy than those in the control group. These differences were observed after 2<sup>nd</sup> or 3<sup>rd</sup> DTaP dose, with the cross-over in antibody concentrations occurring between 4 and 6 months of age.<sup>(41, 47, 55, 56, 62, 68)</sup> In the majority of reviewed RCTs and observational studies, statistically significant differences in antibody levels and avidity disappeared with the receipt of the booster (fourth) DTaP dose after 15 months of age.<sup>(41, 47, 55, 56, 62, 68)</sup> Impact of maternal Tdap immunization in pregnancy on infant response to other vaccine contained antigens was measured in four studies.<sup>(41, 45, 56, 71)</sup> While enhanced immunological response to tetanus and tetanus conjugated vaccines and reduced immunological response to diphtheria and CRM-conjugated vaccines (e.g. meningococcal, pneumococcal vaccines) was noted by several research groups, the clinical impact of these findings was not assessed in the reviewed literature. Given the lack of long-term data, the relevancy of these findings to existing immunization programs therefore remains unknown.<sup>(71, 72)</sup>

### IV.3 Effectiveness of maternal Tdap immunization during pregnancy for preventing pertussis in infants

All studies in which effectiveness of maternal immunization in pregnancy was estimated consistently showed high protection against pertussis in infants less than 3 months of age. The majority of studies identified through the literature review originated from the UK, in which a national maternal immunization program has been implemented since October 2012.<sup>(38-40)</sup> In infants less than 2 months of age, vaccine effectiveness was estimated to be over 90%, with no death observed among infants whose mothers received Tdap prior to 36 weeks of pregnancy.

Vaccine effectiveness was also reported to persist after the receipt of the first three DTaP doses, with immunization in pregnancy resulting in additional protection of up to 70% in children whose mothers received Tdap in pregnancy. Similar results were subsequently reported in studies conducted in the United States of America (US) and Spain.<sup>(73-75)</sup> In one US study that assessed effectiveness of maternal immunization in relation to hospitalization outcomes, infants whose mothers were immunized with Tdap were more likely to have a milder disease course and be older when they developed pertussis, as well as be less likely to have the classic symptoms of pertussis (i.e. paroxysmal cough, apnea, cyanosis).<sup>(73)</sup> In another US study, a significantly lower risk of hospitalization and ICU admission was also observed in infants whose mothers received Tdap.<sup>(74)</sup> In the only study which used surveillance data to estimate maternal Tdap program effectiveness that was conducted in Argentina, significantly lower incidence was observed among infants in parts of the country in which maternal immunization coverage was over 50% compared to those in which coverage was lower.<sup>(76, 77)</sup>

## IV.4 Adverse Events

In total, 16 studies reported on local and systemic adverse events in mothers following Tdap vaccination in pregnancy and 24 studies included data on pregnancy complications or adverse fetal, neonatal or infant outcomes. In addition, the PWG was made aware of the US Vaccine Adverse Event Reporting System (VAERS) data that was presented to ACIP at its meeting in June 2016. Altogether, ten years of passively reported VAERS data and eight years of actively reported longitudinal US Vaccine Safety Datalink (VSD) data have been reported in peer-reviewed publications.

### IV.4.1 Maternal local and systemic adverse events

In four RCTs that reported on the safety of Tdap in pregnancy, no differences in reporting any injection site or systemic reactions were observed independent of the vaccine used in the control group (placebo or tetanus toxoid).<sup>(44-46)</sup> These trials also did not report serious adverse events related to vaccination. This was consistent with the findings of studies that described immunization outcomes following the implementation of national maternal Tdap immunization programs. The most common AEs reported through the VAERS (passive surveillance system) between November 2011 and June 2016, included local (i.e. injection site reactions or extremity myalgia) and systemic events (fever, chills and headache) associated with Tdap immunization.<sup>(78-80)</sup> An analysis of VSD (active surveillance system) data found similar results, with no increased risk determined for neurologic events, incident gestational diabetes, thrombocytopenia, venous thromboembolism or cardiac events (myocarditis, pericarditis, cardiomyopathy, heart failure).<sup>(81, 82)</sup> There were also no differences found in the frequency of fever, allergic reactions or local reactions between women who received Tdap vaccine at less than 2 years compared to more than 5 years after their last dose of a tetanus-containing vaccine. In Argentina, no serious or fatal events were reported during the two years of national maternal immunization program implementation.<sup>(76)</sup>

In published observational studies, results differed according to study location, design and size. In a study that was conducted in Australia local reactions were more frequently reported in pregnant women receiving Tdap alone compared to influenza vaccine alone or together with Tdap.<sup>(83)</sup> A similar study conducted in New Zealand that assessed outcomes of Tdap vaccination with or without influenza vaccine reported high rates of injection site pain (80%).<sup>(84)</sup> Neither of these studies found SAEs to be caused by Tdap vaccination. Similar results were reported in a study that was conducted in Belgium in which stiffness of the arm at the injection site was reported by 74% of study participants, but SAEs were not found to be related to vaccination.<sup>(55)</sup> A study conducted in the US that compared Tdap immunization during and outside pregnancy, found the rates of moderate to severe injection site pain and malaise to be higher in pregnancy, while rates of fever, headaches, injection site swelling and redness were similar between the two study groups.<sup>(85)</sup>

### IV.4.2 Pregnancy-related adverse events

In an analysis of VAERS (passive surveillance system) data, less than 15 events (each) of spontaneous abortion, premature delivery at less than 37 weeks of gestation, stillbirth, chorioamnionitis and oligohydroamnios were reported between 2005 and 2016.<sup>(78-80, 86)</sup> Approximately half of the event submissions to VAERS were made by the two Tdap vaccine manufacturers, which collected this information through their product-specific pregnancy registries.<sup>(87)</sup> An analysis of VSD (active surveillance system) data provided similar findings, with the exception of chorioamnionitis, for which a small but statistically significant increased relative risk (adjusted rate ratio 1.23 [95% CI: 1.17-1.28]) was reported.<sup>(82, 88-90)</sup> However, a subsequent



analysis of this data did not find any increased risks for infant clinical outcomes considered to be associated with chorioamnionitis. In addition, no associations were found between adverse birth outcomes and gestational age at time of Tdap vaccination or timing since prior TT vaccination.<sup>(82, 89)</sup> A small increased risk of chorioamnionitis (relative risk of 1.11 [95% CI: 1.07–1.15]) and postpartum hemorrhage (relative risk of 1.23 [95% CI: 1.18–1.28]) has also been reported following an analysis of commercial insurance claim data of over 207,000 women of whom approximately 150,000 received Tdap during pregnancy.<sup>(91)</sup>

In the UK, an analysis of CPRD (active surveillance system) data in the first six months of national program implementation found stillbirth rates in women immunized with Tdap in pregnancy to be similar to the estimated national stillbirth rate.<sup>(92)</sup> During this time there were no reported cases of placental abruption or vasa previa after vaccination, and no significant differences were reported in the time to delivery and median birth weight between the vaccinated and unvaccinated women.

In RCTs, no differences in the frequency of adverse outcomes in women who received Tdap in pregnancy and women who received placebo (0.9% saline or TT) were reported.<sup>(44-46)</sup> Pregnancy outcomes captured in EMR data that were evaluated in observational studies, similarly, did not show higher frequencies of chorioamnionitis or stillbirth rates in pregnancies in which mothers received one or more doses of Tdap vaccine.<sup>(47, 55, 93-97)</sup> In cohort studies that evaluated pregnancy and infant outcomes without a comparator group, none of the serious adverse events in pregnancy were found to be caused by Tdap vaccination.<sup>(84, 98, 99)</sup>

The PWG was also provided with an analysis of Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) safety data. Between 2007 and 2016, only 8 pregnancy or pregnancy-related events following immunization with Adacel™ (4 reports) or Boostrix™ (4 reports) provided alone or concomitantly with TIV (2 reports) were identified, all considered to be mild or non-related to immunization. These included vaccination site reaction (3 cases), localized or generalized rash (3 cases) and gastrointestinal symptoms (2 cases). Among these, 4 reports included maternal outcomes (2 fully recovered and 2 not yet recovered at time of reporting) and 5 reported on maternal care utilization (2 sought medical care from primary care physician, 1 ER consultation and in 1 case, no further medical care was sought).

#### IV.4.3 Fetal and neonatal adverse events

In the US, studies in which VAERS and VSD surveillance system data was reviewed for adverse birth outcomes found a low number of these events occurring in infants whose mothers received Tdap in pregnancy.<sup>(78-80, 86)</sup> Between 2005 and 2016 only 1% (n=4) of VAERS reports included a major birth defect, while an analysis of VSD data that included pregnancy outcomes from over 197,000 pregnancies did not find an increased risk for infant clinical outcomes that are associated with maternal chorioamnionitis (i.e. newborn transient tachypnea, neonatal sepsis, neonatal pneumonia, respiratory distress syndrome and newborn convulsions). Analysis of VSD data that compared safety outcomes of maternal Tdap vaccination relative to influenza immunization in pregnancy did not find increased risks for microcephaly, preterm delivery, low birth weight and SGA.<sup>(82, 88)</sup> In the UK, a study that reported on the national surveillance system data (CPRD) in the first six months of national maternal Tdap program implementation found no cases of fetal distress or child renal failure.<sup>(92)</sup> An analysis of Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) data from 2007 to 2016 identified the only pregnancy outcome associated with immunization in pregnancy as being a case of a spontaneous abortion in a blighted ovum case.

In RCTs, no differences in the frequency of adverse neonatal outcomes including infants' gestational age, birth weight, Apgar scores, neonatal examination or complications, as well as differences in the infants' growth and development up to 13 months of age were found between women who received Tdap in pregnancy and women who received placebo (0.9% saline or TT).<sup>(44-46)</sup> Similarly, none of the reviewed observational studies that analyzed medical records for AEs post maternal Tdap immunization in pregnancy found increased frequencies in birth defects or differences in 5-minute Apgar scores, cord blood pH values or other adverse birth outcome indicators.<sup>(47, 55, 93-97)</sup> In one study that evaluated hospitalization and other outcomes of children up to 16 months of age, no differences in adverse outcomes were observed based on maternal immunization status, except for low birth weight and NICU admissions (particularly due to preterm birth and anemia) that were more frequently reported in the group of infants whose mothers did not receive Tdap in pregnancy.<sup>(100)</sup> None of the cohort studies that evaluated infant outcomes without a comparator group reported adverse infant outcomes.<sup>(84, 98, 99)</sup>

Although no major safety issues have been detected in the reviewed literature, it should be noted that none of the reviewed studies were sufficiently powered to detect small risk differences. This is particularly relevant to outcomes of interest that are frequent among non-vaccinated individuals (e.g. low birth weight, preterm birth or miscarriage) in which case detection of rare vaccine-associated risks requires well powered trials involving large populations or robust post marketing surveillance data.<sup>(101)</sup>

## V. RECOMMENDATIONS

Following the thorough review of available evidence, NACI issued the following recommendation. In adopting this recommendation and for the purposes of publicly funded program implementation, P/Ts may consider economic factors and other local operational factors. NACI will continue to carefully monitor the scientific developments related to maternal pertussis immunization in pregnancy and will update recommendations as evidence evolves.

**Recommendation: NACI recommends that immunization with Tdap vaccine should be offered in every pregnancy, irrespective of previous Tdap immunization history (Strong NACI Recommendation). NACI concludes that there is good evidence to recommend immunization (Grade A Evidence)**

**Routine maternal Tdap immunization during pregnancy will provide a more robust and complete protection against pertussis in infants compared to immunization during outbreak settings only.**

Tdap immunization in pregnancy has been shown to protect 9 of 10 infants against pertussis less than 3 months of age. No significant safety issues have been detected in the currently available body of scientific literature and no increased risk of serious adverse pregnancy, maternal or infant events have been reported in countries that are routinely offering Tdap vaccine for immunization in pregnancy. Similarly, no serious adverse events have been detected in Canada through CAEFIS. There is currently no indication of a clinically significant change in the priming of the immunological memory of infants exposed to higher maternally derived antibody concentrations following Tdap vaccination in pregnancy. Given the rapid waning of maternal antibody observed in studies, vaccination should be offered in each pregnancy irrespective of immunization history or the interval between pregnancies.



- **NACI recommends that immunization with Tdap vaccine should ideally be provided between 27 and 32 weeks of gestation (Strong NACI Recommendation, Grade A Evidence). Evidence also supports providing maternal Tdap over a wider range of gestational ages, and NACI recommends that it may be provided from 13 weeks up to the time of delivery in view of programmatic and unique patient considerations (Discretionary NACI Recommendation, Grade A/B Evidence).**

Immunization should ideally be offered at 27-32 weeks of gestation, which is supported by the strongest safety and effectiveness data. Immunization between 13 and 26 weeks of gestation may also be considered in some situations (e.g. pregnancies with an increased risk of preterm delivery) to allow for longer placental exposure to higher antibody levels and maximization of antibody transfer. While it is preferable that immunization is administered in sufficient time before birth (i.e. 4 weeks) to allow optimal transfer of antibodies and direct protection of the infant against pertussis, it should be considered until the end of pregnancy, as it has the potential to provide partial protection. If Tdap immunization was provided early in pregnancy (e.g. prior to recognition of pregnancy), it is not necessary to re-immunize after 13 weeks of gestation.

**Table 2. MANAGEMENT OPTIONS**

Various options for timing of pertussis immunization are provided, and the decision on which option is preferable may depend on the considerations itemized in the table below:

Options	Considerations	Decision Points
1. Immunization at 27-32 weeks of gestation	<p><b><u>Safety</u></b></p> <ul style="list-style-type: none"> <li>• Strong safety data in third trimester</li> </ul> <p><b><u>Effectiveness</u></b></p> <ul style="list-style-type: none"> <li>• Effectiveness data primarily span vaccination at 27-36 weeks of gestation.</li> </ul> <p><b><u>Immunogenicity</u></b></p> <ul style="list-style-type: none"> <li>• Peak maternal anti-pertussis antibody levels are achieved approximately 4 weeks following vaccination</li> <li>• Placental transfer of maternal antibodies is optimal in third trimester</li> </ul> <p><b><u>Feasibility or Acceptability</u></b></p> <ul style="list-style-type: none"> <li>• Could be paired with routine prenatal visit during which</li> </ul>	<p>Optimal balance between safety data, clinical opportunities, limited antibody waning potential, efficient antibody formation and placental transfer for term pregnancies.</p> <p>This option is supported by the strongest safety and effectiveness data of all the options, and allows enough time for the antibody response to fully develop in pregnancy.</p> <p>Vaccination can be paired with routine maternal visits, but may not provide protection for some preterm births.</p>

	<p>gestational diabetes screening is offered (24-28 weeks of gestation)</p>	
<p>2. Immunization at 13-26 weeks of gestation</p>	<p><b><u>Safety</u></b></p> <ul style="list-style-type: none"> <li>Fewer safety data in second trimester</li> </ul> <p><b><u>Effectiveness</u></b></p> <ul style="list-style-type: none"> <li>Effectiveness data not stratified for immunization in second trimester (includes immunization in both second and third trimester).</li> </ul> <p><b><u>Immunogenicity</u></b></p> <ul style="list-style-type: none"> <li>Peak maternal anti-pertussis antibody levels are achieved approximately 4 weeks following vaccination</li> <li>Some reports have shown greater antibody concentrations in infants following vaccination at 13-25 weeks compared to <math>\geq 26</math> weeks</li> <li>Earlier vaccine administration in second trimester has been shown to result in higher antibody avidity (binding)</li> </ul> <p><b><u>Feasibility or Acceptability</u></b></p> <ul style="list-style-type: none"> <li>Could be paired with routine prenatal visits, either after detailed anatomical ultrasound is reviewed (typically done between 18-22 weeks of gestation) or when gestational diabetes screening is performed (24-28 weeks of gestation)</li> </ul>	<p>Safety data are fewer for second trimester, and effectiveness data are not stratified for immunization during second trimester.</p> <p>Second trimester vaccination increases clinical opportunities to offer vaccination and ensures optimal antibody formation and transfer for both term and preterm infants. For preterm deliveries, a narrow window of opportunity exists between onset of transplacental antibody transfer at 20 weeks and delivery</p>
<p>3. Immunization before 13 weeks of gestation</p>	<p><b><u>Safety</u></b></p> <ul style="list-style-type: none"> <li>Limited safety data in first</li> </ul>	<p>Safety data are limited before 13 weeks, and effectiveness data are not stratified for first trimester</p>

	<p>trimester</p> <p><b><u>Effectiveness</u></b></p> <ul style="list-style-type: none"> <li>No effectiveness data stratified for immunization prior to 13 weeks of gestation</li> </ul> <p><b><u>Immunogenicity</u></b></p> <ul style="list-style-type: none"> <li>Maternal antibodies will start to wane prior to term delivery</li> <li>Placental transfer of maternal antibodies is minimal prior to third trimester</li> </ul> <p><b><u>Feasibility or Acceptability</u></b></p> <ul style="list-style-type: none"> <li>If vaccine is administered prior to detailed anatomical ultrasound, fetal anomalies and other first trimester pregnancy-related complications may be misattributed to the vaccine</li> <li>The vaccine may not be considered acceptable by patients and clinicians in the first trimester of pregnancy</li> </ul>	<p>immunization.</p> <p>When given early in pregnancy antibody may wane before term delivery</p> <p>There is a risk of adverse events in pregnancy being misattributed to vaccination.</p>
<p>4. Immunization after 32 weeks of gestation</p>	<p><b><u>Safety</u></b></p> <ul style="list-style-type: none"> <li>Strong safety data in third trimester</li> </ul> <p><b><u>Effectiveness</u></b></p> <ul style="list-style-type: none"> <li>Effectiveness data primarily span vaccination at 27-36 weeks of gestation.</li> </ul> <p><b><u>Immunogenicity</u></b></p> <ul style="list-style-type: none"> <li>Placental transfer of maternal antibodies is optimal in third trimester.</li> <li>Peak maternal anti-pertussis antibody levels are achieved approximately 4 weeks</li> </ul>	<p>The strongest safety and effectiveness data are from the third trimester.</p> <p>This option may not allow sufficient time (i.e. 4 weeks) for the development and transfer of maternal antibodies before delivery. Late immunization will not provide protection for most preterm births.</p> <p>There may be fewer clinical opportunities to offer vaccination in late pregnancy compared to earlier vaccination.</p>

	<p>following vaccination.</p> <p><b><u>Feasibility or Acceptability</u></b></p> <ul style="list-style-type: none"> <li>• Clinical opportunities for vaccination exist with frequent routine prenatal visits towards the end of pregnancy.</li> </ul>	
--	--	--

## VI. RESEARCH AND EVALUATION PRIORITIES

Based on the experience of maternal influenza immunization in pregnancy, the large numbers needed to detect rare outcomes and the potential for maternal pertussis vaccination in pregnancy to affect overall pertussis control in the longer term, further research and evaluation is strongly recommended and should be funded as part of any new program. Research to address the following outstanding questions related to immunization in pregnancy is encouraged:

- further work on determining the long-term impact of maternal vaccination in pregnancy on vaccine effectiveness in children and adults (e.g. long-term effect on disease epidemiology as a result of lower infant antibody levels);
- surveillance on mother-infant dyads that have received vaccine;
- safety and impact of repeated Tdap in subsequent pregnancies;
- safety of immunization earlier in pregnancy;
- optimal timing for Tdap administration, resulting in optimal transplacental antibody transfer and infant protection;
- cost-effectiveness of maternal pertussis immunization during pregnancy in the Canadian context;
- the impact of mothers' own childhood primary immunization series with either whole cell versus acellular pertussis;
- development of more effective infant pertussis vaccines.

Implementation research and evaluation is needed to identify the best settings for delivery of vaccine to optimize uptake and determine how to overcome any health care system barriers or acceptability barriers to achieving good coverage.

Additional research pertaining to broader knowledge gaps concerning immunization against pertussis is required to complement research related to immunization in pregnancy. Areas of particular interest include:

- determination of correlates of protection
- impact on infant responses to and protection from vaccines conjugated with TT- and CRM-carrier proteins (e.g. pneumococcal)

## VII. SURVEILLANCE AND MONITORING ISSUES

Pertussis has been a nationally reported disease since 1924. Ongoing and systematic data collection, analysis, interpretation and timely dissemination is fundamental to planning, implementation, evaluation, and evidence-based decision-making. To support such efforts, NACI encourages surveillance improvements in the following areas:

- improved data quality, including completeness of information particularly immunization status;
- enhanced pertussis surveillance to detect outbreaks quickly and understand the burden of disease in different age groups;
- disease surveillance to determine the impact of changing immunization programs, with particular focus on invasive pneumococcal disease (IPD)
- investigating the use of a case definition that allows for milder cases of pertussis.<sup>(102)</sup>;
- active safety evaluation and surveillance including use of linked administrative data
- monitoring the occurrence of rare safety events following maternal vaccination in pregnancy through long-term follow up of large cohorts;
- improving methods of assessing vaccine coverage including developing methods to monitor coverage of maternal immunization in pregnancy (ideally through comprehensive immunization registries);
- improving collaboration between public health and industry in Canada and internationally on monitoring disease activity, vaccine safety and program outcomes.

## TABLES

A detailed analysis of the relevant studies, including evidence tables with quality appraisal for individual studies, is presented in the NACI *Literature Review on Immunization in Pregnancy with Tetanus Toxoid, Reduced Diphtheria Toxoid and Reduced Acellular Pertussis (Tdap) Vaccine: Safety, Immunogenicity and Effectiveness*.

**Table 3. Ranking Individual Studies: Levels of Evidence Based on Research Design**

Level	Description
I	Evidence from randomized controlled trial(s).
II-1	Evidence from controlled trial(s) without randomization.
II-2	Evidence from cohort or case-control analytic studies, preferably from more than one centre or research group using clinical outcome measures of vaccine efficacy.
II-3	Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence.
III	Opinions of respected authorities, based on clinical experience, descriptive studies and case reports, or reports of expert committees.

**Table 4. Ranking Individual Studies: Quality (internal validity) Rating of Evidence**

Quality Rating	Description
Good	A study (including meta-analyses or systematic reviews) that meets all design-specific criteria* well.
Fair	A study (including meta-analyses or systematic reviews) that does not meet (or it is not clear that it meets) at least one design-specific criterion* but has no known "fatal flaw".
Poor	A study (including meta-analyses or systematic reviews) that has at least one design-specific* "fatal flaw", or an accumulation of lesser flaws to the extent that the results of the study are not deemed able to inform recommendations.

\* General design specific criteria are outlined in Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. *Am J Prev Med* 2001;20:21-35.

**Table 5. NACI Recommendations: Strength of Recommendation and Strength of Evidence**

STRENGTH OF NACI RECOMMENDATION	STRENGTH OF EVIDENCE
<b>Based on factors not isolated to strength of evidence (e.g. public health need)</b>	<b>Based on assessment of the body of evidence</b>
<p><b>Strong</b> “should/should not be offered”</p> <ul style="list-style-type: none"> <li>➤ Known advantages outweigh known disadvantages (“should”), OR known disadvantages outweigh known advantages (“should not”)</li> <li>➤ Implication: A strong recommendation applies to most populations/patients and should be followed unless a clear and compelling rationale for an alternative approach is present</li> </ul>	<p>A - <i>good evidence</i> to recommend</p> <p>B – <i>fair evidence</i> to recommend</p> <p>C – <i>conflicting evidence</i>, however other factors may influence decision-making</p> <p>D – <i>fair evidence</i> to recommend against</p> <p>E – <i>good evidence</i> to recommend against</p> <p>I – <i>insufficient evidence</i> (in quality or quantity), however other factors may influence decision-making</p>
<p><b>Discretionary</b> “may be considered”</p> <ul style="list-style-type: none"> <li>➤ Known advantages closely balanced with known disadvantages, OR uncertainty in the evidence of advantages and disadvantages exists</li> <li>➤ Implication: A discretionary recommendation may be considered for some populations/patients in some circumstances. Alternative approaches may be reasonable.</li> </ul>	<p>A - <i>good evidence</i> to recommend</p> <p>B – <i>fair evidence</i> to recommend</p> <p>C – <i>conflicting evidence</i>, however other factors may influence decision-making</p> <p>D – <i>fair evidence</i> to recommend against</p> <p>E – <i>good evidence</i> to recommend against</p> <p>I – <i>insufficient evidence</i> (in quality or quantity), however other factors may influence decision-making</p>

## LIST OF ABBREVIATIONS

<b>Abbreviation</b>	<b>Term</b>
ACIP	Advisory Committee on Immunization Practices (US)
BSA	Bovine Serum Albumin
CAEFISS	Canadian Adverse Events Following Immunization Surveillance System
CDC	Centers for Disease Control and Prevention (US)
CI	Confidence intervals
CIG	Canadian Immunization Guide
CNDSS	Canadian Notifiable Disease Surveillance System
CPRD	Clinical Practice Research Database (UK)
DAD	Discharge Abstract Database
DIP	Diphtheria toxin/toxoid
DTaP	Diphtheria and tetanus toxoids, acellular pertussis vaccine
DTwP	Diphtheria and tetanus toxoids, whole cell pertussis vaccine
EU	Endotoxin Unit
FHA	Pertussis filamentous hemagglutinin
FIM	Fimbriae
FIM 2/3	Pertussis fimbriae
IMPACT	Immunization Monitoring Program Active
JCVI	Joint Committee on Vaccination and Immunization (UK)
Lf	Limit of flocculation
LPF	Lymphocyte proliferating factor
PHAC	Public Health Agency of Canada
PRN	Pertactin
PT	Pertussis Toxin
PWG	NACI Diphtheria/Tetanus/ Pertussis/Polio/Haemophilus Influenza B Working Group
RCT	Randomized Controlled Trial
SGA	Small for gestational age
Tdap	Tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis vaccine
TT	Tetanus toxin
The Agency	Public Health Agency of Canada
µg	Microgram
VAERS	Vaccine Adverse Event Reporting (US)
VE	Vaccine effectiveness
VPD	Vaccine-Preventable Diseases
WHO	World Health Organization



## ACKNOWLEDGMENTS

**This statement was prepared by:** Dr. O. Baclic, Dr. M. Tunis, J. Rotondo, M. Saboui, S. Duchesne-Belanger, Dr. J. Brophy, T. Chevalier, C. Moffatt and approved by NACI.

**Pertussis Working Group Members:** Dr. J. Brophy (Chair), Dr. N. Brousseau, Dr. E. Castillo, Dr. N. Crowcroft, Dr. S. Deeks, Dr. I. Gemmill, Dr. S. Halperin, Dr. B. Henry, Dr. M. Naus, Dr. M. Salvadori, Dr. B. Seifert.

**NACI Members:** Dr. C. Quach (Chair), Dr. W. Vaudry (Vice-Chair), Dr. N. Dayneka, Dr. P. DeWals, Dr. S. Deeks, Dr. V. Dubey, Dr. R. Harrison, Dr. M. Lavoie, Dr. C. Rotstein, Dr. M. Salvadori, Dr. B. Sander, Dr. N. Sicard, Dr. R. Warrington.

**Former NACI Members:** Dr. B. Henry, Dr. I. Gemmil, Dr. S. Marchant-Short, Dr. D. Vinh.

**Liaison Representatives:** Dr. J. Brophy (Canadian Association for Immunization Research and Evaluation [CAIRE]), Dr. E. Castillo (Society of Obstetricians and Gynaecologists of Canada), Dr. A. Cohn (Centers for Disease Control and Prevention, United States), Ms. T. Cole (Canadian Immunization Committee), Dr. J. Emili (College of Family Physicians of Canada), Dr. K. Klein (Council of Chief Medical Officers of Health), Dr. C. Mah (Canadian Public Health Association), Dr. D. Moore (Canadian Paediatric Society), Dr. A. Pham-Huy (Association of Medical Microbiology and Infectious Disease [AMMI] Canada).

**Former Liaison Representatives:** Dr. J. Blake (Society of Obstetricians and Gynaecologists of Canada)

**Ex-Officio Representatives:** Dr. (LCdr) K. Barnes (National Defence and the Canadian Armed Forces), Ms. G. Charos (Centre for Immunization and Respiratory Infectious Diseases [CIRID], Public Health Agency of Canada [PHAC]), Dr. G. Coleman (Biologics and Genetic Therapies Directorate [BGTD], Health Canada [HC]), Dr. J. Gallivan (Marketed Health Products Directorate [MHPD], HC), Ms. J. Pennock (CIRID, PHAC), Mr. G. Poliquin (National Microbiology Laboratory, PHAC), Dr. T. Wong (First Nations and Inuit Health Branch [FNIHB], HC).

**NACI gratefully acknowledges the contribution of L. Gamble, Health Library**

## REFERENCES

1. Canadian Paediatric Society, Infectious Diseases and Immunization Committee. IMPACT after 17 years: Lessons learned about successful networking. *Paediatr Child Health (CAN)*. 2009;14(1):33-5.
2. Richards J, Brown A, Homan C. The data quality study of the Canadian Discharge Abstract Database. *Statistics Canada Symposium 2001*; 2001; ; 2001.
3. Brenner R.A., SimonsMorton B.G., Bhaskar B., Das A., Clemens JD. Prevalence and predictors of immunization among inner-city infants: A birth cohort study. *Pediatrics*. 2001;108(3):661-70.
4. Smith T, Rotondo J, Desai S, et al. Pertussis surveillance in Canada: Trends to 2012. *CCDR*. 2014;40(3):21-30.
5. Abu Raya B., Sadarangani M, Rotondo J, et al. Pertussis in Canada, 1996 to 2015. *Vaccine*. In press 2018.
6. Public Health Agency of Canada. Vaccine preventable diseases in Canada: Surveillance report to December 31, 2015. *Can Commun Dis Rep*. In press 2017.
7. Chambers C, Skowronski D, Hoang L, et al.. Pertussis surveillance trends in British Columbia, Canada, over a 20-year Period: 1993-2013. *CCDR*. 2014;40(3):31-41.
8. Fathima S, Ferrato C, Lee BE, Simmonds K, Yan L, Mukhi SN, et al. Bordetella pertussis in sporadic and outbreak settings in Alberta, Canada, July 2004 - December 2012. *BMC Infect Dis*. 2014;14(1).
9. British Columbia Annual Summary of Reportable Diseases 2015 [Internet]. British Columbia, Canada: British Columbia Centre for Disease Control; 2016 [updated September 3, 2016; cited November 3, 2017]. Available from: <http://www.bccdc.ca/resource-gallery/Documents/Statistics%20and%20Research/Statistics%20and%20Reports/Epid/Annual%20Reports/2015CDAnnualReportFinal.pdf>.
10. Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: Microbiology, Disease, Treatment, and Prevention. *Clin Microbiol Rev*. 2016 Jul;29(3):449-86.
11. Straney L, Schibler A, Ganeshalingham A, Alexander J, Festa M, Slater A, et al. Burden and outcomes of severe pertussis infection in critically ill infants. *Pediatr Crit Care Med*. 2016;17(8):735-42.
12. Silva A, Rotondo J, et al. Pertussis hospitalizations in Canada, 1990 to 2015. *Vaccine*. In press 2018.
13. Brooks J, Gilbert N, Rotondo J, et al. Pertussis toxin antibody levels in a cohort of pregnant women in Canada. *CCDR*. In press 2017.

14. Bigham M., Konrad S., Van Buynder P., Van Buynder J., IsaacRenton J., ElSherif M., et al. Low pertussis toxin antibody levels in two regional cohorts of Canadian pregnant women. *Vaccine*. 2014 12 Nov 2014;32(48):6493-8.
15. Mooi FR, de Greeff SC. The case for maternal vaccination against pertussis. *Lancet Infect Dis*. 2007 Sep;7(9):614-24.
16. Van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in infants. *Pediatr Infect Dis J*. 2005 May;24(5 Suppl):S62-5.
17. Campbell P, McIntyre P, Quinn H, Hueston L, Gilbert GL, McVernon J. Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia. *PLoS One*. 2012;7(4):e35874.
18. de Greeff SC, de Melker HE, van Gageldonk PGM, Schellekens JFP, van der Klis FRM, Mollema L, et al. Seroprevalence of Pertussis in the Netherlands: Evidence for Increased Circulation of *Bordetella pertussis*. *PLoS One*. 2010;5(12):e14183. doi:10.1371/journal.pone.0014183.
19. Plotkin SA. Correlates of protection induced by vaccination. *Clinical and Vaccine Immunology*. 2010 July 2010;17(7):1055-65.
20. Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2006 Mar 24;55(RR-3):1-34.
21. Bisgard KM, Pascual FB, Ehresmann KR, Miller CA, Cianfrini C, Jennings CE, et al. Infant pertussis: who was the source? *Pediatr Infect Dis J*. 2004 Nov;23(11):985-9.
22. Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, Gerber M, et al. Transmission of *Bordetella pertussis* to young infants. *Pediatr Infect Dis J*. 2007 Apr;26(4):293-9.
23. Wiley KE, Zuo Y, Macartney KK, McIntyre PB. Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy. *Vaccine*. 2013 Jan 11;31(4):618-25.
24. Wendelboe AM, Hudgens MG, Poole C, Van Rie A. Estimating the role of casual contact from the community in transmission of *Bordetella pertussis* to young infants. *Emerg Themes Epidemiol*. 2007 Oct 19;4:15.
25. De Greeff S.C., Mooi F.R., Westerhof A., Verbakel J.M.M., Peeters M.F., Heuvelman C.J., et al. Pertussis disease burden in the household: How to protect young infants. *Clinical Infectious Diseases*. 2010 15 May 2010;50(10):1339-45.
26. Crowcroft S, Booy R, Harrison T. Erratum: Severe and unrecognised: Pertussis in UK infants (*Archives of Disease in Childhood* (2003)88(802-806)). *Arch Dis Child*. 2006;91(5):453.

27. Crowcroft N.S., Booy R., Harrison T., Spicer L., Britto J., Mok Q., et al. Severe and unrecognised: Pertussis in UK infants. *Arch Dis Child*. 2003 01 Sep 2003;88(9):802-6.
28. Baron S, Njamkepo E, Grimprel E, Begue P, Desenclos J-, Drucker J, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: Thirty years after a routine use of vaccination. *Pediatr Infect Dis J*. 1998;17(5):412-8.
29. Bonmarin I, Levy-Bruhl D, Baron S, Guiso N, Njamkepo E, Caro V. Pertussis surveillance in French hospitals: Results from a 10 year period. *Euro Surveill*. 2007;12(1):34-8.
30. Halperin SA, Wang EE, Law B, Mills E, Morris R, Dery P, et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program--Active (IMPACT). *Clin Infect Dis*. 1999 Jun;28(6):1238-43.
31. Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. *Pediatr Infect Dis J*. 2003 Jul;22(7):628-34.
32. Elliott E, McIntyre P, Ridley G, Morris A, Massie J, McEniery J, et al. National study of infants hospitalized with pertussis in the acellular vaccine era. *Pediatr Infect Dis J*. 2004 Mar;23(3):246-52.
33. Jardine A, Conaty SJ, Lowbridge C, Staff M, Vally H. Who gives pertussis to infants? Source of infection for laboratory confirmed cases less than 12 months of age during an epidemic, Sydney, 2009. *Commun Dis Intell*. 2010;34(2):116-21.
34. Vaccine uptake in Canadian adults: Results from the 2014 adult National Immunization Coverage Survey (aNICS) [Internet]. Canada: Government of Canada; 2016 [updated February 24, 2016; cited November 3, 2017]. Available from: <https://www.canada.ca/en/public-health/services/publications/healthy-living/vaccine-uptake-canadian-adults-results-2014-adult-national-immunization-coverage-survey.html>.
35. Dodds L, McNeil SA, Fell DB, Allen VM, Coombs A, Scott J, et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. *CMAJ*. 2007 Feb 13;176(4):463-8.
36. Table 102-4504: Mean age of mother at time of delivery (live births), Canada, provinces and territories [Internet]. Canada: Statistics Canada; 2017 [updated October 18, 2017; cited November 3, 2017]. Available from: <http://www5.statcan.gc.ca/cansim/a26?lang=eng&retrLang=eng&id=1024504&paSer=&pattern=&stByVal=1&p1=1&p2=38&tabMode=dataTable&csid>.
37. Table 6-2 Live births, Canada - Age and parity of mother [Internet]. Canada: Statistics Canada; 2015 [updated November 27, 2015; cited November 3, 2017]. Available from: <http://www.statcan.gc.ca/pub/84f0210x/2009000/t008-eng.htm>.
38. Amirthalingam G., Andrews N., Campbell H., Ribeiro S., Kara E., Donegan K., et al. Effectiveness of maternal pertussis vaccination in England: An observational study. *The Lancet*. 2014 25 Oct 2014;384(9953):1521-8.

39. Amirthalingam G, Campbell H, Ribeiro S, Fry NK, Ramsay M, Miller E, et al. Sustained Effectiveness of the Maternal Pertussis Immunization Program in England 3 Years Following Introduction. *Clin Infect Dis*. 2016 Dec 1;63(suppl 4):S236-43.
40. Dabrera G., Amirthalingam G., Andrews N., Campbell H., Ribeiro S., Kara E., et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012-2013. *Clinical Infectious Diseases*. 2015 01 Feb 2015;60(3):333-7.
41. Ladhani SN, Andrews NJ, Southern J, Jones CE, Amirthalingam G, Waight PA, et al. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator. *Clin Infect Dis*. 2015 Dec 1;61(11):1637-44.
42. Sanofi Pasteur Limited. Adacel Product Monograph; June 11, 2012.
43. GlaxoSmithKline Inc. Boostrix Product Monograph; March 14, 2017.
44. Munoz FM, Bond NH, Maccato M, Pinell P, Hammill HA, Swamy GK, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. *JAMA*. 2014 May 7;311(17):1760-9.
45. Hoang HT, Leuridan E, Maertens K, Nguyen TD, Hens N, Vu NH, et al. Pertussis vaccination during pregnancy in Vietnam: Results of a randomized controlled trial Pertussis vaccination during pregnancy. *Vaccine*. 2016 Jan 2;34(1):151-9.
46. Villarreal Perez J.Z., Ramirez Aranda J.M., de la O Cavazos M., Zamudio Osuna M.D.J., Perales Davila J., Ballesteros Elizondo M.R., et al. Randomized clinical trial of the safety and immunogenicity of the Tdap vaccine in pregnant Mexican women. *Human Vaccines and Immunotherapeutics*. 2017 02 Jan 2017;13(1):128-35.
47. Maertens K, Cabore RN, Huygen K, Vermeiren S, Hens N, Van Damme P, et al. Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age. *Vaccine*. 2016 Jun 30;34(31):3613-9.
48. Abu Raya B, Sruogo I, Bamberger E, Kessel A. The avidity of pertussis antibodies following gestational acellular pertussis immunization: Reply to Maertens. *Vaccine*. 2015 Oct 13;33(42):5490-1.
49. Vilajeliu A., Gonce A., Lopez M., Costa J., Rocamora L., Rios J., et al. Combined tetanus-diphtheria and pertussis vaccine during pregnancy: Transfer of maternal pertussis antibodies to the newborn. *Vaccine*. 2015 18 Feb 2015;33(8):1056-62.
50. Huygen K, Caboré RN, Maertens K, Van Damme P, Leuridan E. Humoral and cell mediated immune responses to a pertussis containing vaccine in pregnant and nonpregnant women. *Vaccine*. 2015;33(33):4117-23.

51. Abu Raya B, Srugo I, Kessel A, Peterman M, Vaknin A, Bamberger E. The Decline of Pertussis-Specific Antibodies After Tetanus, Diphtheria, and Acellular Pertussis Immunization in Late Pregnancy. *J Infect Dis*. 2015 Dec 15;212(12):1869-73.
52. Abu Raya B., Srugo I., Kessel A., Peterman M., Bader D., Peri R., et al. The induction of breast milk pertussis specific antibodies following gestational tetanus-diphtheria-acellular pertussis vaccination. *Vaccine*. 2014 Sep 29 2014;32(43):5632-7.
53. De Schutter S, Maertens K, Baerts L, De Meester I, Van Damme P, Leuridan E. Quantification of vaccine-induced antipertussis toxin secretory IgA antibodies in breast milk: comparison of different vaccination strategies in women. *Pediatr Infect Dis J*. 2015 Jun;34(6):e149-52.
54. Maertens K, Hoang TTH, Nguyen TD, Cabore RN, Duong TH, Huygen K, et al. The Effect of Maternal Pertussis Immunization on Infant Vaccine Responses to a Booster Pertussis-Containing Vaccine in Vietnam. *Clin Infect Dis*. 2016 Dec 1;63(suppl 4):S197-204.
55. Maertens K, Cabore RN, Huygen K, Hens N, Van Damme P, Leuridan E. Pertussis vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study. *Vaccine*. 2016;34(1):142-50.
56. Hardy-Fairbanks AJ, Pan SJ, Decker MD, Johnson DR, Greenberg DP, Kirkland KB, et al. Immune responses in infants whose mothers received Tdap vaccine during pregnancy. *Pediatr Infect Dis J*. 2013 Nov;32(11):1257-60.
57. Healy C.M., Rench M.A., Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. *Clinical Infectious Diseases*. 2013 15 Feb 2013;56(4):539-44.
58. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. *Am J Obstet Gynecol*. 2011 Apr;204(4):334.e1,334.e5.
59. Abu Raya B, Srugo I, Kessel A, Peterman M, Bader D, Gonen R, et al. The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels - a prospective study. *Vaccine*. 2014 Oct 7;32(44):5787-93.
60. Goldfarb I.T., Jennewein M., Cosgrove C., Brown J., Krykbaeva M., Cooperrider J.H., et al. Maternal Tdap: How do antibodies protect newborns against pertussis? Netherlands: The Pregnancy Meeting. United States. 216 (1 Supplement 1) (pp S205-S206); Mosby Inc.; 2017.
61. Maertens K, Cabore RN, Huygen K, Hens N, Van Damme P, Leuridan E. Pertussis vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study. *Vaccine*. 2016 Jan 2;34(1):142-50.
62. Cabore RN, Maertens K, Dably A, Leuridan E, Van Damme P, Huygen K. Influence of maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in Belgium. *Virulence*. 2017 Feb 22;1-10.



63. Fallo AA, Neyro SE, Manonelles GV, Lara C, Hozbor D, Zintgraff J, et al. Prevalence of Pertussis Antibodies in Maternal Blood, Cord Serum, and Infants From Mothers With and Those Without Tdap Booster Vaccination During Pregnancy in Argentina. *Journal of the Pediatric Infectious Diseases Societ.* 2016 Dec 30.
64. Vilajeliu A, Ferrer L, Munros J, Gonce A, Lopez M, Costa J, et al. Pertussis vaccination during pregnancy: Antibody persistence in infants. *Vaccine.* 2016 Jul 19;34(33):3719-22.
65. Abu Raya B, Bamberger E, Almog M, Peri R, Srugo I, Kessel A. Immunization of pregnant women against pertussis: the effect of timing on antibody avidity. *Vaccine.* 2015 Apr 15;33(16):1948-52.
66. Naidu MA, Muljadi R, Davies-Tuck ML, Wallace EM, Giles ML. The optimal gestation for pertussis vaccination during pregnancy: a prospective cohort study. *Am J Obstet Gynecol.* 2016 Aug;215(2):237.e1,237.e6.
67. Eberhardt CS, Blanchard-Rohner G, Lemaitre B, Boukrid M, Combescure C, Othenin-Girard V, et al. Maternal Immunization Earlier in Pregnancy Maximizes Antibody Transfer and Expected Infant Seropositivity Against Pertussis. *Clin Infect Dis.* 2016 Apr 1;62(7):829-36.
68. Kent A, Ladhani SN, Andrews NJ, Matheson M, England A, Miller E, et al. Pertussis Antibody Concentrations in Infants Born Prematurely to Mothers Vaccinated in Pregnancy. *Pediatrics.* 2016 Jul;138(1).
69. Eberhardt CS, Blanchard-Rohner G, Lemaitre B, Combescure C, Othenin-Girard V, Chilin A, et al. Pertussis Antibody Transfer to Preterm Neonates After Second- Versus Third-Trimester Maternal Immunization. *Clin Infect Dis.* 2017 Apr 15;64(8):1129-32.
70. Gandhi M, Devaraj S, Sangi-Haghpeykar H, Mastrobattista J. The effect of body mass index on post-vaccination maternal and neonatal pertussis antibody levels. *J Reprod Immunol.* 2015 Nov;112:34-7.
71. Maertens K., Burbidge P., van Damme P., Goldblatt D., Leuridan E. Pneumococcal Immune Response in Infants Whose Mothers Received Tdap Vaccination During Pregnancy. *Pediatr Infect Dis J.* 2017(pagination):ate of Pubaton: 10 Ar 2017.
72. Wood N, Siegrist C. Neonatal immunization: where do we stand? *Curr Opin Infect Dis.* 2011 Jun;24(3):190-5.
73. Winter K, Cherry JD, Harriman K. Effectiveness of Prenatal Tetanus, Diphtheria, and Acellular Pertussis Vaccination on Pertussis Severity in Infants. *Clinical Infectious Diseases.* 2016 Sep 13.
74. Baxter R, Bartlett J, Fireman B, Lewis E, Klein NP. Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis. *Pediatrics.* 2017 May;139(5).
75. Bellido-Blasco J, Guiral-Rodrigo S, Miguez-Santiyan A, Salazar-Cifre A, Gonzalez-Moran F. A case-control study to assess the effectiveness of pertussis vaccination during pregnancy on newborns, Valencian community, Spain, 1 March 2015 to 29 February 2016. *Euro Surveillanc:*

Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin. 2017 Jun 01;22(22).

76. Vizzotti C, Juarez MV, Bergel E, Romanin V, Califano G, Sagradini S, et al. Impact of a maternal immunization program against pertussis in a developing country. *Vaccine*. 2016 Nov 12.

77. Vizzotti C., Neyro S., Katz N., Juarez M.V., Perez Carrega M.E., Aquino A., et al. Maternal immunization in Argentina: A storyline from the prospective of a middle income country. *Vaccine*. 2015 25 Nov 2015;33(47):6413-9.

78. Moro PL. Update on the safety of maternal tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap): Introduction and Enhanced Surveillance of Tdap Vaccine Safety in Pregnancy in VAERS. Meeting of the Advisory Committee on Immunization Practices (ACIP); June 22-23, 2016; Atlanta, Georgia. USA: Advisory Committee on Immunization Practices (ACIP); 2016.

79. Moro PL, Cragan J, Tepper N, Zheteyeva Y, Museru O, Lewis P, et al. Enhanced surveillance of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines in pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2011-2015. *Vaccine*. 2016 Apr 29;34(20):2349-53.

80. Zheteyeva YA, Moro PL, Tepper NK, Rasmussen SA, Barash FE, Revzina NV, et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. *Am J Obstet Gynecol*. 2012 Jul;207(1):59.e1,59.e7.

81. Kharbanda E.O., VazquezBenitez G., Lipkind H.S., Klein N.P., Cheetham T.C., Naleway A.L., et al. Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013. *Vaccine*. 2016 10 Feb 2016;34(7):968-73.

82. Sukumaran L, McCarthy NL, Kharbanda EO, Weintraub ES, Vazquez-Benitez G, McNeil MM, et al. Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. *Obstet Gynecol*. 2015 Nov;126(5):1069-74.

83. Regan A.K., Tracey L.E., Blyth C.C., Richmond P.C., Effler PV. A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy. *Vaccine*. 2016 29 Apr 2016;34(20):2299-304.

84. Petousis-Harris H, Walls T, Watson D, Paynter J, Graham P, Turner N. Safety of Tdap vaccine in pregnant women: an observational study. *BMJ Open*. 2016;6(4):e010911.

85. Fortner K.B., Edwards K.M., Broder K.R., Jimenez N., Zhu Y., Walter E.B., et al. Reactogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women. American Journal of Obstetrics and Gynecology. Conference: 36th Annual Meeting of the Society for Maternal-Fetal Medicine: The Pregnancy Meeting. Atlanta, GA United States. Conference Start: 20160201. Conference End: 20160206. Conference Publication:(TRUNCATED). 2016 January 2016;214(1 SUPPL. 1):S193-4.

86. Datwani H, Moro PL, Harrington T, Broder KR. Chorioamnionitis following vaccination in the Vaccine Adverse Event Reporting System. *Vaccine*. 2015 Jun 17;33(27):3110-3.



87. Wang M., Khromava A., Mahmood A., Dickson N. Pregnant women receiving tetanus-diphtheria-acellular pertussis (Tdap) vaccine: 6 Years of adacel vaccine pregnancy registry data. *Pharmacoepidemiol Drug Saf.* 2011 August 2011;20:S60-1.
88. DeSilva M, Vazquez-Benitez G, Nordin JD, Lipkind HS, Romitti PA, DeStefano F, et al. Tdap Vaccination During Pregnancy and Microcephaly and Other Structural Birth Defects in Offspring. *JAMA.* 2016 Nov 1;316(17):1823-5.
89. Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Klein NP, Cheetham TC, Naleway A, et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. *JAMA.* 2014 Nov 12;312(18):1897-904.
90. DeSilva M., VazquezBenitez G., Nordin J.D., Lipkind H.S., Klein N.P., Cheetham T.C., et al. Maternal Tdap vaccination and risk of infant morbidity. *Vaccine.* 2017 22 June 2017;35(29):3655-60.
91. Layton JB, Butler AM, Li D, Boggess KA, Weber DJ, McGrath LJ, et al. Prenatal Tdap immunization and risk of maternal and newborn adverse events. *Vaccine.* 2017 Jul 24;35(33):4072-8.
92. Donegan K, King B, Bryan P. Safety of pertussis vaccination in pregnant women in UK: observational study. *BMJ.* 2014;349:g4219.
93. Judy A., Singh A., Lee H., Gaskari S., Brodzinsky L., Vik J., et al. Tdap vaccination safety in pregnancy: A comparison of neonatal and obstetric outcomes among women receiving antepartum and postpartum vaccination. *American Journal of Obstetrics and Gynecology.* Conference: 35th Annual Meeting of the Society for Maternal-Fetal Medicine: The Pregnancy Meeting. San Diego, CA United States. Conference Publication: (var.pagings). 212 (1 SUPPL. 1) (pp S300-S301); Mosby Inc.; 2015.
94. Berenson AB, Hirth JM, Rahman M, Laz TH, Rupp RE, Sarpong KO. Maternal and infant outcomes among women vaccinated against pertussis during pregnancy. *Hum Vaccin Immunother.* 2016 Aug 2;12(8):1965-71.
95. Morgan J.L., Baggari S.R., McIntire D.D., Sheffield JS. Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination. *Obstet Gynecol.* 2015 28 Jun 2015;125(6):1433-8.
96. Shakib JH, Korgenski K, Sheng X, Varner MW, Pavia AT, Byington CL. Tetanus, diphtheria, acellular pertussis vaccine during pregnancy: pregnancy and infant health outcomes. *J Pediatr.* 2013 Nov;163(5):1422,6.e1-4.
97. Walls T, Graham P, Petousis-Harris H, Hill L, Austin N. Infant outcomes after exposure to Tdap vaccine in pregnancy: an observational study. *BMJ Open.* 2016 Jan 06;6(1):e009536.
98. Klein NP, Hansen J, Lewis E, Lyon L, Nguyen B, Black S, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. *Pediatr Infect Dis J.* 2010 Jul;29(7):613-7.

99. Talbot EA, Brown KH, Kirkland KB, Baughman AL, Halperin SA, Broder KR. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. *Vaccine*. 2010 Nov 23;28(50):8001-7.

100. Zerbo O, Chan B, Goddard K, Lewis N, Bok K, Klein NP, et al. Kaiser Permanente Northern California pregnancy database: Description and proof of concept study. *Vaccine*. 2016 Nov 4;34(46):5519-23.

101. De Serres G, Skowronski DM. Re: "Detectable Risks in Studies of the Fetal Benefits of Maternal Influenza Vaccination". *Am J Epidemiol*. 2017 May 1;185(9):860-1.

102. WHO-recommended surveillance standard of pertussis [Internet]. Geneva, Switzerland: The World Health Organization; 2013 [updated August 10, 2003; cited November 3, 2017]. Available from: [http://www.who.int/immunization/monitoring\\_surveillance/burden/vpd/surveillance\\_type/passive/pertussis\\_standards/en/](http://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/passive/pertussis_standards/en/).